The Challenge of Access to Oncology Drugs in Canada Harvard Case Solution & Analysis

In recent years, many states with publicly funded health care have started using cost-effectiveness analysis (CEA) along with review of clinical data as a tool to assess the entire benefit of a brand new drug to the society and set priorities with regards to medical care budget. Cost efficiency was officially included into the Ontario drug review system in the year 1993 and the Canadian drug-review scheme in 2003.

The dilemma of using cost effectiveness has gotten increasingly controversial in recent years: that they were frequently classified as being cost effective. Costs although some just approved cancer drugs cost $3,000 to $6,000 or more for one treatment cycle. This note reviews many of the contending interests in disagreements over drug funding and dilemmas about healthcare lending decisions in the existence of limited budgets.

The Challenge of Access to Oncology Drugs in Canada case study solution

PUBLICATION DATE: December 01, 2009 PRODUCT #: 909E20-HCB-ENG

This is just an excerpt. This case is about TECHNOLOGY & OPERATIONS

The Challenge of Access to Oncology Drugs in Canada Case Solution Other Similar Case Solutions like

The Challenge of Access to Oncology Drugs in Canada

Share This